{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:55:55Z","timestamp":1781528155179,"version":"3.54.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.msard.2026.107151","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:41:13Z","timestamp":1774078873000},"page":"107151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Long-term outcomes of cladribine tablets in multiple sclerosis: Treatment completion, persistence, and subsequent therapy transitions in Southeast Europe"],"prefix":"10.1016","volume":"109","author":[{"given":"Magdalena","family":"Krbot Skori\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Brecl Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Rajda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy","family":"Jer\u010dinovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Abi\u010di\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Adamec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uro\u0161","family":"Rot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Barun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Gabeli\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alenka","family":"Horvat Ledinek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Gomezelj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e9ter","family":"Kliv\u00e9nyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3360-1748","authenticated-orcid":false,"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107151_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2023.578164","article-title":"Cladribine tablets in people with relapsing multiple sclerosis: a real-world multicentric study from southeast European MS centers","volume":"382","author":"Adamec","year":"2023","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2026.107151_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.104951","article-title":"Real-world use of cladribine tablets (completion rates and treatment persistence) in patients with multiple sclerosis in England: the CLARENCE study","volume":"79","author":"Brownlee","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107151_bib0003","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.3389\/fneur.2018.01150","article-title":"The effect of disease modifying therapies on disability progression in multiple sclerosis: a systematic overview of meta-analyses","volume":"9","author":"Claflin","year":"2019","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107151_bib0004","doi-asserted-by":"crossref","DOI":"10.1177\/1756285617753365","article-title":"Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study","volume":"11","author":"Comi","year":"2018","journal-title":"Ther. Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107151_bib0005","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s40120-022-00430-z","article-title":"The place of immune reconstitution therapy in the management of relapsing multiple sclerosis in France: an expert consensus","volume":"12","author":"De S\u00e8ze","year":"2023","journal-title":"Neurol. Ther."},{"issue":"6","key":"10.1016\/j.msard.2026.107151_bib0006","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: An ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107151_bib0007","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.msard.2026.107151_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200415","article-title":"The Italian multiple sclerosis register experience with cladribine: impact on relapses, PIRA, and treatment sequencing strategies evaluation","volume":"12","author":"Guerra","year":"2025","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"10.1016\/j.msard.2026.107151_bib0009","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3325\/cmj.2022.63.379","article-title":"Treatment of relapsing multiple sclerosis - recommendations of the Croatian Neurological Society","volume":"63","author":"Habek","year":"2022","journal-title":"Croat. Med. J."},{"key":"10.1016\/j.msard.2026.107151_bib0010","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40120-022-00422-z","article-title":"Treatment with cladribine tablets beyond year 4: a position statement by Southeast European Multiple Sclerosis Centers","volume":"12","author":"Habek","year":"2023","journal-title":"Neurol. Ther."},{"key":"10.1016\/j.msard.2026.107151_bib0011","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40262-018-0695-9","article-title":"The clinical pharmacology of cladribine tablets for the treatment of relapsing multiple sclerosis","volume":"58","author":"Hermann","year":"2019","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.msard.2026.107151_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106398","article-title":"First insights into the safety and effectiveness of additional courses with cladribine tablets under real-world conditions","volume":"97","author":"Kleinschnitz","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107151_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.105704","article-title":"Real-world therapy management of patients with multiple sclerosis receiving cladribine tablets beyond year 4 - results from a German cladribine cohort","volume":"88","author":"Kowarik","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"3","key":"10.1016\/j.msard.2026.107151_bib0014","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/1352458520921087","article-title":"Real-world effectiveness of cladribine for Australian patients with multiple sclerosis: an MSBase registry substudy","volume":"27","author":"Lizak","year":"2021","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107151_bib0015","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1001\/jama.2020.26858","article-title":"Diagnosis and treatment of multiple sclerosis: a review","volume":"325","author":"McGinley","year":"2021","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.msard.2026.107151_bib0016","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1080\/14656566.2020.1792885","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets: an expert opinion","volume":"21","author":"Meuth","year":"2020","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.msard.2026.107151_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2022.104459","article-title":"Expert opinion on the long-term use of cladribine tablets for multiple sclerosis: systematic literature review of real-world evidence","volume":"69","author":"Oreja-Guevara","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2026.107151_bib0018","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/13524585211012227","article-title":"Effectiveness and safety of cladribine in MS: real-world experience from two tertiary centres","volume":"28","author":"Pfeuffer","year":"2022","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107151_bib0019","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13023-023-02789-0","article-title":"Treatment of relapsing multiple sclerosis in Hungary - consensus recommendation from the Hungarian neuroimmunology society","volume":"18","author":"Rajda","year":"2023","journal-title":"Orphanet. J. Rare Dis."},{"key":"10.1016\/j.msard.2026.107151_bib0020","first-page":"28","article-title":"Disease-modifying therapy for multiple sclerosis in Slove-nia: analysis of 20 years of treatment","author":"Rot","year":"2022","journal-title":"RAD CASA - Med. Sci."},{"key":"10.1016\/j.msard.2026.107151_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2025.106275","article-title":"Additional Cladribine tablets treatment courses in multiple sclerosis patients. A retrospective observational study in Latin American countries","volume":"94","author":"Silva","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107151_bib0022","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756286420935019","article-title":"Expert opinion on the use of cladribine tablets in clinical practice","volume":"13","author":"S\u00f8rensen","year":"2020","journal-title":"Ther. Adv. Neurol. Disord."},{"issue":"2 Suppl","key":"10.1016\/j.msard.2026.107151_bib0023","first-page":"S15","article-title":"Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis","volume":"19","author":"Tullman","year":"2013","journal-title":"Am. J. Manag. Care."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034826001872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T12:26:04Z","timestamp":1781526364000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034826001872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":23,"alternative-id":["S2211034826001872"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107151","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term outcomes of cladribine tablets in multiple sclerosis: Treatment completion, persistence, and subsequent therapy transitions in Southeast Europe","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107151"}}